Search all trials

Find therapies in clinical trials near you – page 2

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Bladder transitional cell carcinoma

Recruiting

Registered drugNo placebo

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Erdafitinib

Contact Research Centre

Bladder transitional cell carcinoma

Recruiting

Registered drugNo placebo

Study of Mitomycin-C with Electromotive Drug Administration before Surgery in Patients with Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Mitomycin

Contact Research Centre

Bladder transitional cell carcinoma+1

Not yet recruiting

Registered drugNo placebo

Study on Avelumab for Patients with Advanced Urothelial Cancer After Initial Chemotherapy

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Avelumab

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Registered drugNo placebo

Study of N-803 combined with BCG treatment for patients with early-stage bladder cancer that has not invaded the muscle wall

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Registered drug

Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment

Registered drug

Austria

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Durvalumab

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Investigational

Study on the Safety and Effectiveness of Alpha1H for Adults with Non-Muscle Invasive Bladder Cancer Awaiting Tumor Removal Surgery

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Alpha1H

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Registered drugNo placebo

Study of Eciskafusp Alfa and BCG for Patients with High-Risk Bladder Cancer Not Responding to BCG Treatment

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:RO7284755

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Registered drugNo placebo

Study Comparing Gemcitabine and Mitomycin for Patients with Intermediate Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo

Sweden

Participants:18–64 years · 65+ years
Substances:Gemcitabine

Contact Research Centre

Bladder transitional cell carcinoma+2

Not recruiting

Registered drugNo placebo

Study of Durvalumab and Tremelimumab for Patients with Advanced Unresectable Urothelial Cancer

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Registered drug

Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Registered drugNo placebo

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cetrelimab

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

InvestigationalNo placebo

Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cetrelimab

Contact Research Centre

Find therapies in clinical trials near you – page 2

33 trials match your criteria

Bladder transitional cell carcinoma

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Bladder transitional cell carcinoma

Study of Mitomycin-C with Electromotive Drug Administration before Surgery in Patients with Non-Muscle Invasive Bladder Cancer

Bladder transitional cell carcinoma+1

Study on Avelumab for Patients with Advanced Urothelial Cancer After Initial Chemotherapy

Bladder transitional cell carcinoma

Study of N-803 combined with BCG treatment for patients with early-stage bladder cancer that has not invaded the muscle wall

Bladder transitional cell carcinoma

Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment

Bladder transitional cell carcinoma

Study on the Safety and Effectiveness of Alpha1H for Adults with Non-Muscle Invasive Bladder Cancer Awaiting Tumor Removal Surgery

Bladder transitional cell carcinoma

Study of Eciskafusp Alfa and BCG for Patients with High-Risk Bladder Cancer Not Responding to BCG Treatment

Bladder transitional cell carcinoma

Study Comparing Gemcitabine and Mitomycin for Patients with Intermediate Risk Non-Muscle Invasive Bladder Cancer

Bladder transitional cell carcinoma+2

Study of Durvalumab and Tremelimumab for Patients with Advanced Unresectable Urothelial Cancer

Bladder transitional cell carcinoma

Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

Bladder transitional cell carcinoma

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Bladder transitional cell carcinoma

Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.